As shown in Figure 5E, pretreatment of CLL B-lymphocytes with Ibrutinib completely prevented CXCL12-induced activation of RhoA, similarly to healthy B-lymphocytes. This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.